Methods This was a single-arm interventional, single-center, open-label pilot study. Interventions included monthly infusions of the IVIG preparation Privigen®, dose 0.4 gram/kg, for 6 months.

By Reuters February 14, 20172:44 PM UTCUpdated ago Feb 14 (Reuters) - CSL Ltd * FDA accepts CSL Behring's biologics license application supplement for using privigen® to treat Chronic ...